Boehringer Ingelheim Presents Results of Spesolimab in P-II (Effisayil 1) Trial for the Treatment of Generalized Pustular Psoriasis at AAD 2022
Shots:
- The P-II (Effisayil 1) trial evaluates spesolimab (900mg, IV) vs PBO in a ratio (2:1) in 53 patients with GPP
- The results showed a significant clearance of skin pustules within the 1st wk. after treatment & was sustained over 12wks., 84.4% of patients had no visible pustules after the 12wk. trial & 81.3% had clear/almost clear skin, improvements in GPP flare symptoms i.e., pain & fatigue, clinical improvements were consistent across patient subgroups
- AEs were reported in 66% vs 56%, infections (17% vs 6%), serious AEs in 6%, 2 patients have drug reactions with eosinophilia & systemic symptoms. The US FDA has accepted a BLA & granted Priority Review, ODD, BTD for spesolimab to treat GPP flares
Ref: PR Newswire | Image: Boehringer Ingelheim
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
